Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
peptide
Biotech
Gilead to buy PepStar’s oral IL-23 drug for $1.3B upfront
The deal positions Gilead as a would-be challenger to Johnson & Johnson’s Icotyde across a range of inflammatory diseases.
Nick Paul Taylor
Oct 23, 2026 9:00am
Verdiva axes GLP-1 switching trial over ‘market evolution’
Oct 14, 2026 10:13am
Axoltis misses the mark in ph. 2 ALS study, but won't give up
Sep 15, 2026 3:00am
With $30M, Oorja Bio breathes new life into fibrosis candidate
May 20, 2026 10:31am
Fierce Pharma
FDA advisory committee to discuss action on unapproved peptides
Apr 15, 2026 5:15pm
Syneron closes $150M round to support peptide platform
Apr 3, 2026 9:31am
